Regulation of Pancreatic Endocrine Function by Cholecystokinin: Studies with MK-329, a Nonpeptide Cholecystokinin Receptor Antagonist*
- 1 May 1990
- journal article
- research article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 70 (5), 1312-1318
- https://doi.org/10.1210/jcem-70-5-1312
Abstract
A cholecystokinin (CCK) receptor antagonist, MK-329, was used to explore the physiological role of CCK in regulating pancreatic endocrine function in humans. The ability of CCK to increase plasma pancreatic polypeptide (PP) concentrations and blockade of this effect with MK-329 were evaluated in a double blind, balanced, four-period cross-over study. Eight subjects received single oral doses of 0.5, 2, or 10 mg MK-329 or placebo, followed by an iv infusion of CCK-8 (34 ng/kg·h). In placebo-treated subjects, PP increased from basal levels of 70 ± 15 (±se) to peak values of 291 ± 58 pg/mL after CCK infusion (P < 0.05 compared to basal). This increase in plasma PP concentration was inhibited in a dose-dependent fashion by MK-329, with 10 mg antagonizing the stimulatory effect of CCK infusion by nearly 80%. Second, the effect of MK-329 on meal-stimulated pancreatic endocrine responses was evaluated by giving placebo or 10 mg MK-329 2 h before ingestion of a mixed meal. Eight subjects were treated in a randomized two-period cross-over fashion. With placebo treatment, peak postprandial plasma insulin, glucagon, and glucose concentrations were 101 ± 8 μU/mL, 195 ± 15 pg/mL, and 150 ± 10 mg/dL, respectively (all P < 0.05). The integrated PP response following the meal was 56.3 ± 11.1 ng/mL·minute. With MK-329 treatment, the integrated PP concentration was reduced to 33.9 ± 2.2 ng/mLmin (P < 0.05 compared to placebo treatment). Mean postprandial insulin, glucagon, and glucose concentrations did not differ between placebo and MK-329 treatments. We conclude that CCK receptor blockade with 10 mg MK-329 does not alter plasma insulin, glucagon, or glucose responses to a mixed meal. However, the observation that physiological concentrations of CCK increase plasma levels of PP, and the finding that CCK receptor blockade selectively attenuates the postprandial increase in plasma PP concentrations support a physiological role for CCK in regulating PP secretion.Keywords
This publication has 29 references indexed in Scilit:
- Release of pancreatic polypeptide in humans by infusion of cholecystokininGastroenterology, 1980
- Neural regulation of pancreatic hormone secretion by the C-terminal tetrapeptide of CCKNature, 1980
- Discrepancies between the Doses of Cholecystokinin or Caerulein-Stimulating Exocrine and Endocrine Responses in Perfused Isolated Rat PancreasJCI Insight, 1979
- Effect of eating and gastrointestinal hormones on human colonic myoelectrical and motor activityGastroenterology, 1978
- Release of immunoreactive somatostatin from the pancreas in response to glucose, amino acids, pancreozymin-cholecystokinin, and tolbutamide.JCI Insight, 1977
- The Effects of Secretin, Pancreozymin, and Gastrin on Insulin and Glucagon Secretion in Anesthetized Dogs *JCI Insight, 1967
- The Two-Period Change-Over Design and Its Use in Clinical TrialsBiometrics, 1965
- Immunoassay of Insulin: Two Antibody System: Plasma Insulin Levels of Normal, Subdiabetic and Diabetic RatsDiabetes, 1963
- Pancreozymin, a stimulant of the secretion of pancreatic enzymes in extracts of the small intestineThe Journal of Physiology, 1943
- A HORMONE MECHANISM FOR GALL-BLADDER CONTRACTION AND EVACUATIONAmerican Journal of Physiology-Legacy Content, 1928